Mark Solakian

Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...

Wilson Sonsini Goodrich & Rosati advised Nature’s Toolbox on the transaction. Nature’s Toolbox (NTx) announced the close of a $47.5 million Series B funding round led by...

Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction. Aqtual announced it has completed a $16 million Series A round of financing co-led by Genoa Ventures,...

Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...

Wilson Sonsini Goodrich & Rosati advised Nohbo in the transaction. Nohbo announced the completion of its Series A funding round, led by Material Impact Fund. While the...

Wilson Sonsini Goodrich & Rosati advised Neuvivo in the deal. Neuvivo announced that it has closed an $11 million round of financing led by PrimeStreet Capital. The funding will...

Wilson Sonsini advised Droplet Biosciences on the deal. Droplet Biosciences announced an $8 million seed investment to establish proof of concept for the company’s lymph diagnostic...

Wilson Sonsini Goodrich & Rosati advised Elucidata on the transaction. TechBio company Elucidata announced that it has raised $16 million in a Series A fundraising, which...

Wilson Sonsini advised Investor Time BioVentures on the deal while WilmerHale represented Phantom Neuro. Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high...

Wilson Sonsini advised Think Bioscience on the deal. Think Bioscience, a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, announced it has...

Wilson Sonsini advised Faeth Therapeutics on the deal. Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led...

Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...